Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MST1R/RON drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MST1R (RON) ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View MST1R Products |
| Gene Delivery | MST1R Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional assay development. |
View MST1R Products |
| Benchmark Ab | Anti-MST1R Recombinant Antibody (Sequence of Narnatumab) Recombinant positive control for binding and functional assays. |
View MST1R Products |
| Validator | MST1R siRNA Set Target-specific knockdown verification in target-expressing cancer cell lines. |
View MST1R Products |
| Related Target A | MET (c-Met) High-homology family member. Crucial for cross-reactivity and off-target safety profiling. |
View MET Products |
| Related Target B | MSP (MST1) The endogenous ligand of MST1R. Essential for ligand-blocking and competitive inhibition assays. |
View MSP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-homology screening with c-Met to prevent off-target toxicity | Sequence-verified human MST1R and c-Met proteins available with >95% purity for precise ELISA/SPR selectivity assays. |
| Epitope mapping for internalization-competent ADC candidates | HEK293-expressed ECD-Fc fusions preserving native conformational epitopes and post-translational glycosylations. |
| Lack of standardized assay positive controls | Clinical benchmark antibody (Narnatumab biosimilar) synthesized with verified variable region sequences. |
| Target validation and specificity assurance | Sequence-validated siRNA pools for robust gene knockdown to confirm antibody/small-molecule specificity. |
Live MST1R/RON R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MST1R (RON) therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to antibody-drug conjugates (ADCs) and bispecific antibodies. Because MST1R is frequently co-expressed with MET and EGFR in epithelial cancers, and rapidly internalizes upon ligand binding, it has emerged as a premier target for payload delivery. As first-generation tyrosine kinase inhibitors (TKIs) face limitations in selectivity, the next wave of R&D is targeting highly specific extracellular epitopes to avoid c-Met cross-reactivity while exploiting MST1R's rapid internalization kinetics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Preclinical/Phase I Candidates | Triple-Negative Breast Cancer (TNBC), NSCLC, Pancreatic Cancer | Internalization Assay (Requires high-purity, natively glycosylated ECD-Fc) |
| Bispecific Antibody (e.g., MET x RON) | Biotech Innovators | EGFR-TKI Resistant Lung Cancer, Gastric Cancer | Dual-affinity validation (Requires high-purity MST1R and c-Met proteins side-by-side) |
| Monoclonal Antibody (mAb) | Eli Lilly (Narnatumab) | Solid Tumors | Ligand-blocking assays (Requires bioactive-grade MSP and validated biosimilar control) |